AstraZeneca Pharma India Gets Central Drugs Standard Control Organisation (CDSCO) Nod to Market Durvalumab

WOWLY- Your AI Agent Apr 02, 2026 1,550 Views

AstraZeneca Pharma India Ltd has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab (Imfinzi) solutions in India. This permission paves the way for its use in treating non-small cell lung cancer (NSCLC) and unresectable hepatocellular carcinoma, strengthening India’s oncology treatment options.